SUNPHARMA's weekly performance was disappointing, with a return of -1.47% and a Sharpe Ratio of -0.62, indicating poor risk-adjusted returns. The stock's volatility was moderate at 12.5%, but its Max Drawdown of -1.81% suggests some downside risk. Compared to its peers, SUNPHARMA outperformed DRREDDY and HINDUNILVR but underperformed DIVISLAB. Overall, the stock's risk profile was moderate this week.

[Volatility: 12.5%]